<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03623646</url>
  </required_header>
  <id_info>
    <org_study_id>18 VADS 06</org_study_id>
    <nct_id>NCT03623646</nct_id>
  </id_info>
  <brief_title>Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.</brief_title>
  <acronym>CITHARE</acronym>
  <official_title>Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase II, multicenter, open-label study that has been designed to evaluate&#xD;
      the efficacy and the safety of definitive Radiotherapy (RT) (70 Gy) delivered in combination&#xD;
      with the anti-PD-L1 Durvalumab immunotherapy in patients with Human Papilloma Virus&#xD;
      (HPV)-related oropharyngeal squamous cell carcinoma.&#xD;
&#xD;
      In this phase II trial, patients will be assigned in one of the two treatment arms:&#xD;
&#xD;
        -  Arm A (standard arm): Chemoradiotherapy arm&#xD;
&#xD;
        -  Arm B (Experimental arm): Immunotherapy + Radiotherapy arm&#xD;
&#xD;
      Total duration of treatment will be 6 months (at maximum in the experimental arm).&#xD;
&#xD;
      Patients will be followed for a maximum of 2 years following the date of randomization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients alive without progression at 12 months.</measure>
    <time_frame>12 months for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival.</measure>
    <time_frame>24 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival.</measure>
    <time_frame>24 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety will be evaluated using National Cancer Institute Common Toxicity Criteria Adverse Event (NCI-CTCAE) version 4.03.</measure>
    <time_frame>24 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30).</measure>
    <time_frame>24 months for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be evaluated using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Head &amp; Neck 35 (EORTC QLQ-H&amp;N35).</measure>
    <time_frame>24 months for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm A (standard arm): Chemoradiotherapy arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Experimental arm): Immunotherapy + Radiotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemoradiotherapy arm</intervention_name>
    <description>Radiation Therapy in combination with Chemotherapy (Cisplatin)</description>
    <arm_group_label>Arm A (standard arm): Chemoradiotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunotherapy + Radiotherapy arm</intervention_name>
    <description>Radiation Therapy in combination with Immunotherapy drug (Durvalumab)</description>
    <arm_group_label>Arm B (Experimental arm): Immunotherapy + Radiotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Newly diagnosed, histologically proven squamous cell carcinoma of oropharynx T1 N1-N2&#xD;
             or T2-T3 N0 to N2 (AJCC 2018)&#xD;
&#xD;
          2. HPV positive status (positive staining for p16 in immunochemistry)&#xD;
&#xD;
          3. Presence of at least one measurable lesion according to RECIST v1.1 criteria (longest&#xD;
             diameter recorded ≥10 mm with CT scan)&#xD;
&#xD;
          4. No prior anticancer therapy for OSCC&#xD;
&#xD;
          5. Patient eligible for definitive radiochemotherapy&#xD;
&#xD;
          6. Age ≥ 18 years&#xD;
&#xD;
          7. WHO performance status &lt; 2 i.e. 0 or 1&#xD;
&#xD;
          8. Body weight &gt;30kg&#xD;
&#xD;
          9. Life expectancy more than 3 months&#xD;
&#xD;
         10. Adequate Hematology laboratory data within 6 weeks prior to start of treatment:&#xD;
             Absolute neutrophils&gt; 1.5 x 109/L, Platelets ≥ 100 x 109/L, Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
         11. Adequate Biochemistry laboratory data within 6 weeks prior to start of treatment:&#xD;
             Total bilirubin ≤ 1.5 x upper the normal limit, Transaminases ≤ 2.5 xUNL, Alkalin&#xD;
             phosphatases ≤ 5 x UNL, Creatinin clearance ≥ 60 mL/min (Cockcroft), Glycemia ≤ 1.5 x&#xD;
             UNL&#xD;
&#xD;
         12. Adequate Hemostasis laboratory data within 6 weeks prior to start of treatment: TP&#xD;
             within the normal range&#xD;
&#xD;
         13. Women should be post-menopaused or willing to accept the use an effective&#xD;
             contraceptive regimen during the treatment period and at least 3 months (durvalumab&#xD;
             arm) or 6 months (cisplatin arm) after the end of the study treatment. All&#xD;
             non-menopaused women should have a negative pregnancy test within 72 hours prior to&#xD;
             registration. Men should accept to use an effective contraception during treatment&#xD;
             period and at least 3 months (durvalumab arm) or 6 months (cisplatin arm) after the&#xD;
             end of the study treatment&#xD;
&#xD;
         14. Patient is willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up&#xD;
&#xD;
         15. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. T1 N0, T1-T3 N3, T4 N0-N3, p16 + OSCC&#xD;
&#xD;
          2. Previous treatment with another check-point inhibitor&#xD;
&#xD;
          3. Other histologies : UCNT, p16- SCCHN, sino-nasal tumors&#xD;
&#xD;
          4. Patient ineligible for Cisplatin according to the updated SmPC of the drug (including&#xD;
             patient with auditory deficiency, patient with neuropathy induced by previous&#xD;
             Cisplatin treatment or patient treated with prophylactic phenytoin)&#xD;
&#xD;
          5. Metastatic disease&#xD;
&#xD;
          6. Previous radiotherapy, except anterior strictly out of field radiotherapy, received&#xD;
             for treatment of another primary tumor considered in remission in the past 5 years&#xD;
&#xD;
          7. Participation in another therapeutic trial within the 30 days prior to entering this&#xD;
             study&#xD;
&#xD;
          8. Uncontrolled disease such as diabetes, hypertension, symptomatic congestive heart or&#xD;
             pulmonary failure, renal or hepatic chronic diseases... (non-exhaustive list)&#xD;
&#xD;
          9. Clinically significant cardiac disease or impaired cardiac function, such as:&#xD;
&#xD;
               -  Congestive heart failure requiring treatment (New York Heart Association (NYHA)&#xD;
                  Grade ≥ 2), left ventricular ejection fraction (LVEF) &lt; 50% as determined by&#xD;
                  multi-gated acquisition (MUGA) scan or echocardiogram (ECHO), or uncontrolled&#xD;
                  arterial hypertension defined by blood pressure &gt; 140/100 mm Hg at rest (average&#xD;
                  of 3 consecutive readings),&#xD;
&#xD;
               -  History or current evidence of clinically significant cardiac arrhythmias, atrial&#xD;
                  fibrillation and/or conduction abnormality, e.g. congenital long QT syndrome,&#xD;
                  high- Grade/complete AV-blockage&#xD;
&#xD;
               -  Acute coronary syndromes (including myocardial infarction, unstable angina,&#xD;
                  coronary artery bypass graft (CABG), coronary angioplasty, or stenting), &lt; 3&#xD;
                  months prior to screening&#xD;
&#xD;
               -  QT interval adjusted according to Fredericia (QTcF) &gt; 470 msec on screening ECG&#xD;
&#xD;
         10. Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             fraction of RT (exception: systemic corticosteroids at physiologic doses not exceeding&#xD;
             10 mg/day of prednisone or equivalent are allowed as well as steroids as premedication&#xD;
             for hypersensitivity reactions (eg, CT scan premedication) - Topical, inhaled, nasal&#xD;
             and ophthalmic steroids are not prohibited)&#xD;
&#xD;
         11. Active suspected or prior documented autoimmune disease (including inflammatory bowel&#xD;
             disease, celiac disease, irritable bowel syndrome, Wegner's granulomatosis and&#xD;
             Hashimoto's thyroiditis, diverticulitis with the exception of diverticulosis, systemic&#xD;
             lupus erythematosus, Sarcoidosis syndrome). Note: participants with vitiligo or&#xD;
             alopecia, residual hypothyroidism due to autoimmune condition only requiring hormone&#xD;
             replacement, patients with celiac disease controlled by diet alone, psoriasis not&#xD;
             requiring systemic treatment, or conditions not expected to recur in the absence of an&#xD;
             external trigger, are permitted to enroll&#xD;
&#xD;
         12. Known primary immunodeficiency or active HIV (positive HIV 1/2 antibodies)&#xD;
&#xD;
         13. Known active or chronic viral hepatitis or history of any type of hepatitis within the&#xD;
             last 6 months indicated by positive test for hepatitis B surface antigen (HBV sAG) or&#xD;
             hepatitis C virus ribonucleic acid (HCV antibody)&#xD;
&#xD;
         14. History of organ transplant requiring use of immunosuppressive medication&#xD;
&#xD;
         15. History of active tuberculosis (clinical evaluation that includes clinical history,&#xD;
             physical examination and radiographic findings, and TB testing in line with local&#xD;
             practice)&#xD;
&#xD;
         16. Current pneumonitis or interstitial lung disease&#xD;
&#xD;
         17. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, serious chronic gastrointestinal conditions associated with diarrhea, or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirement, substantially increase risk of incurring AEs or compromise the ability of&#xD;
             the patient to give written informed consent&#xD;
&#xD;
         18. History of another primary malignancy except for:&#xD;
&#xD;
               1. Malignancy treated with curative intent and with no known active disease ≥5 years&#xD;
                  before the first dose of IP and of low potential risk for recurrence&#xD;
&#xD;
               2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence&#xD;
                  of disease&#xD;
&#xD;
               3. Adequately treated carcinoma in situ without evidence of disease&#xD;
&#xD;
         19. History of severe allergic reactions to any unknown allergens or any components of the&#xD;
             study drug&#xD;
&#xD;
         20. History of leptomeningeal carcinomatosis&#xD;
&#xD;
         21. Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the&#xD;
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion&#xD;
             criteria&#xD;
&#xD;
               1. Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after&#xD;
                  consultation with the Study Physician&#xD;
&#xD;
               2. Patients with irreversible toxicity not reasonably expected to be exacerbated by&#xD;
                  treatment with durvalumab may be included only after consultation with the Study&#xD;
                  Physician&#xD;
&#xD;
         22. Uncontrolled severe infectious disease, active hemorrhagic syndrome&#xD;
&#xD;
         23. Major surgical procedure (as defined by the Investigator) within 28 days prior to the&#xD;
             first dose of IP&#xD;
&#xD;
         24. Concurrent enrolment in another clinical study, unless it is an observational&#xD;
             (non-interventional) clinical study or during the follow-up period of an&#xD;
             interventional study&#xD;
&#xD;
         25. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note:&#xD;
             Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to&#xD;
             30 days after the last dose of IP&#xD;
&#xD;
         26. Vaccination for yellow fever&#xD;
&#xD;
         27. Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ effective birth control from&#xD;
             screening to 90 days after the last dose of durvalumab monotherapy or 180 days after&#xD;
             the last dose of cisplatin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer Toulouse (IUCT-O)</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2018</study_first_submitted>
  <study_first_submitted_qc>August 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oropharyngeal Squamous Cell Carcinoma</keyword>
  <keyword>Anti PD-L1</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Human Papilloma Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

